Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6436259 | 0.98 | MEN1 (0.50) | MEN1KMT2ADPP7NPC1EPHX2 | |
| SCHEMBL206952 | 0.85 | MEN1 (0.57) | MEN1KMT2ADPP7NPC1ATM | |
| SCHEMBL14205020 | 0.84 | KMT2A (0.46) | MEN1KMT2ANPC1ATMCHRM2 | |
| SCHEMBL8421187 | 0.84 | VSIR (0.44) | ATMMAPTGAA | |
| SCHEMBL13662612 | 0.84 | ATM (0.44) | MEN1KMT2AATMANPEPERAP2 | |
| SCHEMBL15876277 | 0.84 | MTNR1A (0.42) | ATMMAPTGAA | |
| SCHEMBL5190209 | 0.84 | LMNA (0.59) | NPC1RAB9AHDAC1KDM4EALDH1A1 | |
| SCHEMBL1109881 | 0.83 | S1PR1 (0.42) | MEN1KMT2AATMMAPTGAA | |
| SCHEMBL13605089 | 0.83 | ANPEP (0.50) | MEN1KMT2ANPC1EPHX2RAB9A | |
| SCHEMBL8139519 | 0.83 | TPSAB1 (0.45) | ATMANPEPERAP2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| WO-2004087656-A1 | CONJUGATES OF 2,4-ETHANO-BRIDGED AND 2,4-PROPANO-BRIDGED 3,6,9-TRIAZA-NONANOIC ACID, 3N,6N,9,9N-TETRAETHANOIC ACID, AND CORRESPONDING PHOSPHORIC ACID METHYLENE DERIVATIVES AND THE SUBSTITUTION PRODUCTS THEREOF WITH BIOMOLECULES, METHODS FOR THE PRODUCTION THEREOF, AND THE USE OF THE SAME FOR PRODU | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-10-14 | — | — | WO | disclosed |
| EP-0951471-B1 | CYCLOALKYL INHIBITORS OF PROTEIN FARNESYLTRANSFERASE | WARNER LAMBERT CO (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1077945-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1242120-A2 | COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE | Pfizer Limited (GB) | 2002-09-25 | — | — | EP | disclosed |
| CN-1318059-A | Isoquinolines as urokinase inhibitors | PFIZER (US) | 2001-10-17 | — | — | CN | disclosed |
| US-6281194-B1 | E.G., (S)-(1-((4-BENZYLOXY-BENZYL)-(((1-PHENYL-CYCLOBUTYLMETHYL)-CAR BAMOYL)-METHYL)-CARBAMOYL)-2-(1H-IMIDAZOL-4-YL)-ETHYL)-CARBAMI C ACID BENZYL ESTER | WARNER-LAMBERT COMPANY | 2001-08-28 | — | — | US | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
| EP-1077945-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6093731-A | Isoquinolines | PFIZER INC. | 2000-07-25 | — | — | US | disclosed |
| WO-2000005214-A2 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | MEN1 4591/4885KMT2A 4810/4885DPP7 813/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | MEN1 4591/4885KMT2A 4810/4885DPP7 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.